Behavioural symptoms (change from baseline at 26 weeks measured using various scales) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Acceptability · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher acceptability of treatment (as measured by withdrawals from trials… compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Ambulation · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in ambulation compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Survival (long term) Over two years · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in survival (long term) Over two years compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Pain reduction · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in pain reduction compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Urinary continence One week after treatment · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids showed no clear difference in urinary continence One week after treatment compared with moderate‐dose or no corticosteroids (low certainty).
1 finding from 1 review
Local recurrence · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
1 finding from 1 review
Quality of life · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in baseline trough FEV1 · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
1 finding from 1 review
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Hospital admissions · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium probably leads to lower hospital admissions (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium showed no clear difference in mortality (all‐cause) compared with ipratropium (moderate certainty).
1 finding from 1 review
Quality of life ( · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
1 finding from 1 review
Exacerbations · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower patients with one or more exacerbations compared with ipratropium (high certainty).
1 finding from 1 review
Treatment withdrawal · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower withdrawals compared with ipratropium (high certainty).
1 finding from 1 review
Intervention not reported
At least 50% of maximum pain relief over 4 to 6 h · adults with moderate or severe acute postoperative pain
The intervention leads to higher at least 50% of maximum pain relief over 4 to 6 h (high certainty).
1 finding from 1 review
RR 4.1 [2.8, 5.9]
Studies not reported
High
Intervention not reported
Participants with at least 1 adverse event · adults with moderate or severe acute postoperative pain
The intervention showed no clear difference in participants with at least 1 adverse event (moderate certainty).
1 finding from 1 review
RR 1.2 [0.84, 1.7]
Studies not reported
Moderate